Market research
4880.TSE CellSource Co., Ltd
TSE JPY Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 6B
- P/E ratio
- 62.98
- Analyst target
- 880
- Dividend yield
- 1.6%
- Beta
- -0.01
Profile
Instrument facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- JP3423580004
- Market cap
- 6B
- P/E ratio
- 62.98
- Analyst target
- 880
- Dividend yield
- 1.6%
- Beta
- -0.01
About
About CellSource Co., Ltd
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients' adipose tissues, and to prepare platelet-rich plasma from patients' blood; and offers support services for medical facilities providing regenerative medicine therapy. It is also involved in the sale of human stem cell-derived cosmetic ingredients; and Signalift series of anti-aging products, including a serum. The company was incorporated in 2015 and is headquartered in Shibuya, Japan.
Research context
CellSource Co., Ltd appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
0 comments
Sign in to join the 4880.TSE discussion.
No comments yet
Start a focused discussion about 4880.TSE.